La cadena de opciones muestra datos clave de las opciones de acciones de CytomX Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CytomX Therapeutics..

CytomX Therapeutics (NASDAQ:CTMX) Bolsa, Cadena de Opciones

CytomX Therapeutics

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

News

WKSP

Worksport's Terravis Energy Unveils AI-Enhanced Heat Pump Revolutionizing Home Climate Control; Says 20-Day Countdown To Global Reveal Begins

WIIM

Textron shares are trading lower after the company missed Q4 revenue expectations and issued FY25 EPS guidance below estimates.

Seagate Technology shares are trading higher after the company reported Q2 EPS and revenues above analyst estimates.

Deutsche Bank analyst Brian Bedell reiterates State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Hold and lowers the price target from $104 to $103.

Price Target

Reiteration

Analyst Ratings

Deutsche Bank Reiterates Hold on State Street, Lowers Price Target to $103

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) with a Buy and maintains $7 price target.

COCP

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $7 Price Target

Citigroup analyst Asiya Merchant maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $120 to $125.

Citigroup Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $125

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Buy and lowers the price target from $75 to $72.

Deutsche Bank Maintains Buy on H.B. Fuller, Lowers Price Target to $72

Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a Neutral and raises the price target from $142 to $152.

Citigroup Maintains Neutral on 3M, Raises Price Target to $152

Industry partners to provide funding and data to support ACAT&#x2122; model improvements
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT&#x2122;) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

Biotech

General

Simulations Plus And Enabling Technologies Consortium Announce Strategic Collaboration To Advance GastroPlus Enhancements

Global

P&G CFO Says Organic Sales In China Declined 3% In Q2

ROKU

Roku shares are trading higher after Netflix reported strong quarterly earnings.

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Neutral.

ATRA

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

United Airlines shares are trading higher after the company reported better-than-expected Q4 financial results.

IBKR

Interactive Brokers shares are trading higher following better-than-expected Q4 financial results.

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and raises the price target from $80 to $85.

SCHW

Citigroup Maintains Neutral on Charles Schwab, Raises Price Target to $85

The Offering is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.&nbsp;

MCTR

CTRL Group Prices $8M Initial Public Offering Of 2M Common Shares At $4/Share

RVSN

Rail Vision shares are trading higher after the company announced a binding MoU with Sujan Ventures to introduce its safety systems to the Indian railway market.

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Piper Sandler lowered the firm's price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares follow...

CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler

Warning: CTMX is at high risk of performing badly

Analysts fell to the sidelines weighing in on Xenetic Biosciences (XBIO – Research Report) and CytomX Therapeutics (CTMX – Research Report) with ne...

Wall Street Analysts Are Neutral on Top Healthcare Picks

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

JonesResearch analyst Soumit Roy keeps a Buy rating on CytomX Therapeutics (CTMX) with a $7 price target after the company announced the new drug a...

CytomX heading into 'major catalyst year,' says JonesResearch

"CytomX Therapeutics (CTMX) announced updated pipeline priorities and anticipated milestones for 2025. "Our top strategic objective for 2025 is the...

CytomX Therapeutics says focus on development of CRC treatment CX-2051 in FY25

Barclays analyst Peter Lawson maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a price target of $3.50. The co...

CytomX Therapeutics (CTMX) Gets a Buy from Barclays

Wedbush lowered the firm's price target on CytomX Therapeutics (CTMX) to $5 from $8 and keeps an Outperform rating on the shares. The firm notes Cy...

CytomX Therapeutics price target lowered to $5 from $8 at Wedbush

Wedbush analyst Robert Driscoll maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a price target of $5.00. The ...

CytomX Therapeutics (CTMX) Receives a Buy from Wedbush

CytomX falls after portfolio shakeup, job cuts

CANF

CAPR

CHRS

CTMX

CYCN

ENLV

HRTX

XBIO

Press Releases

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

Earnings

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Comments

CytomX Therapeutics

CytomX Therapeutics (CTMX) Opciones

CytomX Therapeutics (NASDAQ:CTMX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL